6th GPCRs-Targeted Drug Discovery Summit

Memo

The GPCR field is entering its next phase of innovation. As biopharma looks beyond GLP-1 for the next breakthrough therapeutic opportunity, advances in AI, structural biology, next-generation screening platforms, and signaling science are transforming how researchers discover, validate, and drug GPCR targets. Yet critical challenges remain, from de-risking orphan receptors and predicting functional activity to translating complex GPCR biology into differentiated medicines. The 6th GPCRs-Targeted Drug Discovery Summit is the industry's only dedicated meeting focused exclusively on advancing GPCR drug discovery across targets, modalities, and therapeutic areas. Bringing together leaders from Eli Lilly, Pfizer, Roche, Recursion Pharmaceuticals, Alphamol, LEMBAS, Kainova Therapeutics, Duke University, University of Miami, and more, this is your opportunity to benchmark the latest advances in AI-enabled discovery, target validation, signaling biology, structural drug design, and next-generation GPCR therapeutics. Whether you're searching for the next target beyond GLP-1, evaluating emerging modalities, or looking to accelerate your GPCR pipeline, join 80+ industry and academic experts shaping the future of GPCR drug discovery. URLs:Tickets: https://go.evvnt.com/3855540-2?pid=5569Brochure: https://go.evvnt.com/3855540-3?pid=5569 Date and Time: On Tue, 02 Mar 2027 08:30 - Thu, 04 Mar 2027 16:15 Venue Details: Revere Hotel Boston Common, 200 Stuart Street, Boston, Massachusetts, 02116, United States Category: Conferences | Science, Health and Medicine | Pharmaceuticals Prices:Drug Developer Pricing - Conference + Focus Day: USD 4507.00,Drug Developer Pricing - Conference Only: USD 3149.00,Drug Developer Pricing - Focus Day Only: USD 779.00,Discounted Pricing - Conference + Focus Day: USD 3907.00,Discounted Pricing - Conference Only: USD 2749.00,Discounted Pricing - Focus Day Only: USD 679.00,Vendor Pricing - Conference + Focus Day: USD 5397.00,Vendor Pricing - Conference Only: USD 3999.00 Speakers: Martin Marro, Executive Director of Cell Pharmacology, Obesity and Complications, Eli Lilly and Co., Zsofia Lengyel Zhand, Principal Scientist, Pfizer, Uwe Grether, Distinguished Scientist, Roche, Jingjing Liu, Associate Director, Abalone Bio, Asli Muvaffak, Head of Biology and Translational Sciences, Abundance Biopharma, Jorg Bentzien, Director of Computational Chemistry, Alkermes plc, Shuguang Yuan, Co-Founder, Alphamol, Benjamin Pelcman, Scientific Advisor, Atrogi, David Cooper, CEO, Biagon Inc, Christel Menet, Chief Scientific Officer, Confo Therapeutics, Yamina Berchiche, Founder, Chief Executive Officer and Chief Scientific Officer, DrGPCR, Chris Dockendorff, Chief Scientific Officer and Chief Executive Officer, Function Therapeutics, Will Barnes, Executive Director and Head of GPCR Biology, Iambic Therapeutics, Stephan Schann, Chief Scientific Officer, Kainova Therapeutics, Zohar Barbash, Chief Technology Officer and Co-Founder, LEMBAS, Reid Olsen, Director of Strategic Drug Discovery Initiatives, Recursion, Manel Kraiem Merabet, Chief Development Officer, SKYMAB Biotherapeutics, Ching-Hsuan Tsai, Executive Director, Head of Molecular Discovery, Structure Therapeutics, David O’Connell, Associate Professor, University College Dublin, Nina Tsvetanova, Associate Professor of Pharmacology and Cancer Biology, Duke Office of Licensing and Ventures, John Janetzko, Assistant Professor, University of Colorado Anschutz Medical Campus, Daniel Isom, Associate Professor of Molecular and Cellular Pharmacology, University of Miami School of Medicine, Sivaraj Sivaramakrishnan, Professor and Head, Genetics Cell Biology and Development, University of Minnesota - Twin Cities, Dmitry Veprintsev, Professor of Molecular and Cellular Pharmacology, University of Nottingham